Merck & Co., Inc. Insider Trading

MRK

Last 12 months

Insiders sold $71.3M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. EVP, General Counsel Jennifer Zachary sold $14.5M on Feb 9, 64% of their stake, outside a plan. The last open-market buy by an executive or director was in Feb 2025.

Net open-market

−$71.3M

0 buys · 20 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Feb 2025

Feb 6, 2025

Get an email when MRK's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 13	Chirfi Guindo EVP, Access, Policy & Comms	SoldNo plan	10,000	$135.00	$1.35M	21%	Form 4
Aug 12	Jennifer Zachary EVP, General Counsel	SoldNo plan	80,315	$133.46	$10.7M	64%	Form 4
Aug 10 – 12	Richard R. Deluca EVP&Pres, Merck Animal Heallth	SoldNo plan 5 parts	45,320	$131.12 average	$5.94M	29%	Form 4
Aug 6	Richard R. Deluca EVP&Pres, Merck Animal Heallth	SoldNo plan 3 parts	6,050	$130.37 average	789K	3.7%	Form 4
Aug 6	Chirfi Guindo EVP, Access, Policy & Comms	SoldNo plan	15,000	$131.00	$1.97M	24%	Form 4
Aug 5	David R. Maraldo EVP & Pres. MMD	SoldNo plan 3 parts	18,706	$128.72 average	$2.41M	51%	Form 4
Aug 5	David Michael Williams EVP,Chief Info&Digital Officer	SoldNo plan 3 parts	52,847	$128.77 average	$6.81M	62%	Form 4
Feb 12	Chirfi Guindo Chief Marketing Officer	SoldNo plan	10,000	$121.46	$1.21M	14%	Form 4
Feb 10	Dean Y Li Executive VP & President, MRL	SoldNo plan	10,235	$117.52	$1.2M	10%	Form 4
Feb 9	Chirfi Guindo Chief Marketing Officer	SoldNo plan	10,000	$118.41	$1.18M	12%	Form 4
Feb 9	Jennifer Zachary EVP, General Counsel	SoldNo plan 3 parts	121,573	$119.15 average	$14.5M	64%	Form 4
Feb 6	David Michael Williams EVP,Chief Info&Digital Officer	SoldNo plan	5,000	$121.91	610K	14%	Form 4
Feb 6	Johannes Jacobus Oosthuizen President, U.S. Market	SoldNo plan	15,000	$121.87	$1.83M	41%	Form 4
Feb 6	Richard R. Deluca EVP&Pres, Merck Animal Heallth	SoldNo plan	37,685	$120.92	$4.56M	19%	Form 4
Feb 5	Chirfi Guindo Chief Marketing Officer	SoldNo plan	20,000	$121.88	$2.44M	20%	Form 4
Feb 4	Dalton E. Smart III SVP Fin. - Global Controller	SoldNo plan 2 parts	6,400	$119.68 average	766K	44%	Form 4
Feb 4	Caroline Litchfield EVP & CFO	SoldNo plan	41,997	$119.61	$5.02M	32%	Form 4
Feb 4	Dean Y Li Executive VP & President, MRL	SoldNo plan	15,087	$118.77	$1.79M	13%	Form 4
Feb 4	Robert M Davis Chairman, CEO & President	SoldNo plan 2 parts	47,434	$118.04 average	$5.6M	9.7%	Form 4
Nov 10, 2025	Cristal N Downing Chief Comm. & Public Afrs Ofcr	SoldNo plan	7,085	$87.00	616K	100%	Form 4
Nov 3, 2025	David Michael Williams EVP,Chief Info&Digital Officer	SoldNo plan	8,614	$83.59	720K	26%	Form 4
Apr 25, 2025	Dalton E. Smart III SVP Fin. - Global Controller	SoldNo plan	4,262	$82.76	353K	35%	Form 4
Feb 19, 2025	Johannes Jacobus Oosthuizen President, U.S. Market	SoldNo plan	8,500	$84.09	715K	22%	Form 4
Feb 13, 2025	David Michael Williams EVP,Chief Info&Digital Officer	SoldNo plan	6,000	$85.34	512K	20%	Form 4
Feb 6, 2025	Inge G Thulin Director	Bought	2,833	$88.25	250K	2833%	Form 4
Feb 6, 2025	Cristal N Downing Chief Comm. & Public Afrs Ofcr	SoldNo plan	2,361	$88.76	210K	25%	Form 4
Feb 5, 2025	Douglas M Baker Jr Director	Bought	15,000	$88.50	$1.33M	1500%	Form 4

Aug 13No plan
Chirfi Guindo
EVP, Access, Policy & Comms · sold 10,000 at $135.00
$1.35M
21% of stake
Aug 12No plan
Jennifer Zachary
EVP, General Counsel · sold 80,315 at $133.46
$10.7M
64% of stake
Aug 10 – 12No plan
Richard R. Deluca
EVP&Pres, Merck Animal Heallth · sold 45,320 at avg $131.12
$5.94M
29% of stake
Aug 6No plan
Richard R. Deluca
EVP&Pres, Merck Animal Heallth · sold 6,050 at avg $130.37
789K
3.7% of stake
Aug 6No plan
Chirfi Guindo
EVP, Access, Policy & Comms · sold 15,000 at $131.00
$1.97M
24% of stake
Aug 5No plan
David R. Maraldo
EVP & Pres. MMD · sold 18,706 at avg $128.72
$2.41M
51% of stake
Aug 5No plan
David Michael Williams
EVP,Chief Info&Digital Officer · sold 52,847 at avg $128.77
$6.81M
62% of stake
Feb 12No plan
Chirfi Guindo
Chief Marketing Officer · sold 10,000 at $121.46
$1.21M
14% of stake
Feb 10No plan
Dean Y Li
Executive VP & President, MRL · sold 10,235 at $117.52
$1.2M
10% of stake
Feb 9No plan
Chirfi Guindo
Chief Marketing Officer · sold 10,000 at $118.41
$1.18M
12% of stake
Feb 9No plan
Jennifer Zachary
EVP, General Counsel · sold 121,573 at avg $119.15
$14.5M
64% of stake
Feb 6No plan
David Michael Williams
EVP,Chief Info&Digital Officer · sold 5,000 at $121.91
610K
14% of stake
Feb 6No plan
Johannes Jacobus Oosthuizen
President, U.S. Market · sold 15,000 at $121.87
$1.83M
41% of stake
Feb 6No plan
Richard R. Deluca
EVP&Pres, Merck Animal Heallth · sold 37,685 at $120.92
$4.56M
19% of stake
Feb 5No plan
Chirfi Guindo
Chief Marketing Officer · sold 20,000 at $121.88
$2.44M
20% of stake
Feb 4No plan
Dalton E. Smart III
SVP Fin. - Global Controller · sold 6,400 at avg $119.68
766K
44% of stake
Feb 4No plan
Caroline Litchfield
EVP & CFO · sold 41,997 at $119.61
$5.02M
32% of stake
Feb 4No plan
Dean Y Li
Executive VP & President, MRL · sold 15,087 at $118.77
$1.79M
13% of stake
Feb 4No plan
Robert M Davis
Chairman, CEO & President · sold 47,434 at avg $118.04
$5.6M
9.7% of stake
Nov 10, 2025No plan
Cristal N Downing
Chief Comm. & Public Afrs Ofcr · sold 7,085 at $87.00
616K
100% of stake
Nov 3, 2025No plan
David Michael Williams
EVP,Chief Info&Digital Officer · sold 8,614 at $83.59
720K
26% of stake
Apr 25, 2025No plan
Dalton E. Smart III
SVP Fin. - Global Controller · sold 4,262 at $82.76
353K
35% of stake
Feb 19, 2025No plan
Johannes Jacobus Oosthuizen
President, U.S. Market · sold 8,500 at $84.09
715K
22% of stake
Feb 13, 2025No plan
David Michael Williams
EVP,Chief Info&Digital Officer · sold 6,000 at $85.34
512K
20% of stake
Feb 6, 2025
Inge G Thulin
Director · bought 2,833 at $88.25
250K
2833% of stake
Feb 6, 2025No plan
Cristal N Downing
Chief Comm. & Public Afrs Ofcr · sold 2,361 at $88.76
210K
25% of stake
Feb 5, 2025
Douglas M Baker Jr
Director · bought 15,000 at $88.50
$1.33M
1500% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MRK, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MRK

CompareIntrinsic value

PFEPfizer Inc.

$30.79+2.63%30

JNJJohnson & Johnson

$276.34+3.82%53

ABBVAbbVie Inc.

$294.83+3.09%49

BMYBristol-Myers Squibb Company

$64.20+4.04%61

LLYEli Lilly and Company

$1,418.07+0.62%73

GILDGilead Sciences Inc.

$174.49+4.19%48

AMGNAmgen Inc.

$478.48+3.73%45

Held by ETFs

MRK is in 452 US ETFs. The largest of them, with MRK's weight in each:

Spot a number that looks wrong? Check it in MRK's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MRK

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.